Sanofi’s Lemtrada Accepted for FDA Review – Analyst Blog

Sanofi ‘s ( SNY ) resubmitted supplemental Biologics License Application (sBLA) for Lemtrada (alemtuzumab) has been accepted by the U.S. …read more

You may also like